 Reviva Pharmaceuticals Holdings Inc NASDAQ: RVPH has announced the full details of its Phase 2 trial evaluating its lead drug candidate, RP5063 brilaroxazine, for Acute Schizophrenia. Brilaroxazine demonstrated high affinity and selectivity for key serotonin receptors 5-HT1A2A2B7 through its combination of potent affinity and selectivity for target receptors implicated for schizophrenia and its comorbid symptoms. 